Switzerland-based healthcare company Roche announced on Monday that it has received its first FDA approval for the company's paroxysmal nocturnal haemoglobinuria (PNH) treatment drug, PIASKY (crovalimab).
The FDA accepted a biologics license application for crovalimab in September 2023 and subsequently approved it in June 2024 for treating PNH in adults and adolescents aged 13 years and older.
The approval has increased competition between the company and the current market leader, AstraZeneca. Other pharma companies are also geared up to introduce their respective lead assets.
PiaSky is also undergoing review by other regulatory authorities, including those in Europe and Taiwan.
Scopio Labs secures fourth FDA clearance
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA